BACKGROUND: Lymphatic and/or blood vessel tumoral invasion (LBVI) is a common histopathologic finding of gastric carcinomas, which could make it an additional cost efficient marker and help in the detection of patients at risk for recurrence. MATERIALS AND METHODS: The subjects of this study were 144 patients with primary gastric adenocarcinoma, who consecutively underwent surgery. LBVI was evaluated by H&E staining and complementary with immunohistochemical staining with anti-CD34. Intratumoral levels of EGFR were analyzed with a radioligand technique, whereas c-erbB-2 and tPA were determined by ELISA methods; pS2, cathepsin D and hyaluronic acid by immunoradiometric assays; and VEGFR-1 and -2 by immunohistochemical assays. The mean follow-up period for these patients was 33.1 months. RESULTS: LBVI was present in 46 patients (31.9%). The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors. In addition, statistical analysis demonstrated that LBVI was significantly associated with a poorer overall patients' survival in the univariate analysis (P = 0.0001) as well as in the multivariate analysis (P = 0.009). However, our results failed to show any significant relationship between LBVI and any of the intratumoral biological parameters studied. CONCLUSION: LBVI provides additional useful information that could be applied to identify gastric cancer patients at risk for recurrence, who might be candidates for further adjuvant therapies.
BACKGROUND: Lymphatic and/or blood vessel tumoral invasion (LBVI) is a common histopathologic finding of gastric carcinomas, which could make it an additional cost efficient marker and help in the detection of patients at risk for recurrence. MATERIALS AND METHODS: The subjects of this study were 144 patients with primary gastric adenocarcinoma, who consecutively underwent surgery. LBVI was evaluated by H&E staining and complementary with immunohistochemical staining with anti-CD34. Intratumoral levels of EGFR were analyzed with a radioligand technique, whereas c-erbB-2 and tPA were determined by ELISA methods; pS2, cathepsin D and hyaluronic acid by immunoradiometric assays; and VEGFR-1 and -2 by immunohistochemical assays. The mean follow-up period for these patients was 33.1 months. RESULTS: LBVI was present in 46 patients (31.9%). The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors. In addition, statistical analysis demonstrated that LBVI was significantly associated with a poorer overall patients' survival in the univariate analysis (P = 0.0001) as well as in the multivariate analysis (P = 0.009). However, our results failed to show any significant relationship between LBVI and any of the intratumoral biological parameters studied. CONCLUSION: LBVI provides additional useful information that could be applied to identify gastric cancerpatients at risk for recurrence, who might be candidates for further adjuvant therapies.
Authors: S Ishigami; S Natsugoe; S Hokita; M Tokushige; T Saihara; T Watanabe; K Aridome; H Iwashige; T Aikou Journal: Ann Surg Oncol Date: 1999 Apr-May Impact factor: 5.344
Authors: Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain Journal: Science Date: 2002-04-25 Impact factor: 47.728
Authors: S Guadagni; P I Reed; B J Johnston; G De Bernardinis; M Catarci; M Valenti; F di Orio; M Carboni Journal: Br J Surg Date: 1993-03 Impact factor: 6.939
Authors: P Raigoso; A Junco; A Andicoechea; A Gonzalez; J L García-Muñiz; M T Allende; M García-Morán; F Vizoso Journal: Int J Biol Markers Date: 2000 Jan-Mar Impact factor: 3.248
Authors: T Arigami; S Natsugoe; Y Uenosono; H Arima; Y Mataki; K Ehi; S Yanagida; S Ishigami; S Hokita; T Aikou Journal: Br J Cancer Date: 2005-09-19 Impact factor: 7.640
Authors: Chun-Yan Du; Jing-Gui Chen; Ye Zhou; Guang-Fa Zhao; Hong Fu; Xue-Ke Zhou; Ying-Qiang Shi Journal: World J Gastroenterol Date: 2012-07-21 Impact factor: 5.742